Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Official title:
A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease
This study is designed to determine the maximal tolerated dose of Ruxolitinib in combination with nilotinib in patients with chronic myeloid leukemia (CML).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01593254 -
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
|
Phase 2 | |
| Recruiting |
NCT03610971 -
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
|
Phase 2 | |
| Completed |
NCT03045120 -
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
|
||
| Recruiting |
NCT03934372 -
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01850004 -
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
|
Phase 2 | |
| Terminated |
NCT02627677 -
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
|
Phase 3 | |
| Completed |
NCT01660906 -
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
|
Phase 4 | |
| Completed |
NCT01933906 -
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
|
Phase 1 | |
| Completed |
NCT01914484 -
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
|
Phase 1/Phase 2 |